Phase II Study of Pazopanib and Topotecan in Cervical Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 31, 2016

Primary Completion Date

August 31, 2019

Conditions
Cervical Cancer
Interventions
DRUG

Pazopanib

600 mg by mouth daily in a 28 day cycle.

DRUG

Topotecan

0.25 mg by mouth daily for 21 days of a 28 day cycle.

BEHAVIORAL

Phone Call

During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER